Srinagar Magazine

Smallpox Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

 Breaking News
  • No posts were found

Smallpox Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

March 22
05:44 2023
Smallpox Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

DelveInsight’s, “Smallpox Pipeline Insight, 2023,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Smallpox pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Smallpox Pipeline Insight Report

 

  • DelveInsight’s Smallpox Pipeline report depicts a robust space with 04+ active players working to develop 04+ pipeline therapies for Smallpox treatment.

 

  • The leading Smallpox Companies include Chimerix, BioFactura, Tonix Pharmaceuticals Holding Corp, Bavarian Nordic A/S, ViRAZE, HK inno.N, and others.

 

  • The promising Smallpox therapies include FD MVA-BN, Vaccinia virus: ACAM2000 smallpox vaccine, MVA-BN® (IMVAMUNE), TPOXX, and others.

 

  • The Smallpox companies and academics are working to assess challenges and seek opportunities that could influence Smallpox R&D. The Smallpox pipeline therapies under development are focused on novel approaches to treat/improve Smallpox.

 

Request a sample and discover the recent breakthroughs happening in the Smallpox Pipeline landscape @ Smallpox Pipeline Outlook Report

 

Smallpox Overview

Smallpox is an acute contagious disease caused by the variola virus, a member of the orthopoxvirus family. It was one of the most devastating diseases known to humanity and caused millions of deaths before it was eradicated. Smallpox is a category A pathogen which are those organisms/biological agents that pose the highest risk to national security and public health because they can be easily disseminated or transmitted from person to person, result in high mortality rates and have the potential for major public health impact, might cause public panic and social disruption, and require special action for public health preparedness.

 

Recent Developmental Activities in the Smallpox Treatment Landscape

 

  • Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2022. BCV is designed to improve treatment of viral infections by enhancing drug delivery to the intracellular site of viral replication. BCV effectively penetrates cells via its lipid conjugate, releasing the nucleotide analog cidofovir, which then acts to inhibit virus replication.

 

  • TNX-801 is a novel, live virus vaccine grown in cell culture.1 Tonix is developing TNX-801 as a potential smallpox preventing vaccine for widespread immunization and national stockpile. Though it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that Tonix believes it may lower toxicity and offer potential safety advantages over existing vaccinia-based vaccines, which have been associated with adverse side effects such as myocarditis/pericarditis. *Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S.

 

  • Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. BCV is currently under review for approval at the U.S.

 

For further information, refer to the detailed Smallpox Drugs Launch, Smallpox Developmental Activities, and Smallpox News, click here for Smallpox Ongoing Clinical Trial Analysis

 

Smallpox Pipeline Therapeutics Assessment

There are approx. 4+ key companies which are developing the therapies for Smallpox. The companies which have their Smallpox drug candidates in the most advanced stage, i.e. phase preregistration include, Chimerix.

 

Find out more about the Smallpox Pipeline Segmentation, Therapeutics Assessment, and Smallpox Emerging Drugs @ Smallpox Treatment Landscape

 

Scope of the Smallpox Pipeline Report

 

  • Coverage- Global

 

  • Smallpox Companies- Chimerix, BioFactura, Tonix Pharmaceuticals Holding Corp, Bavarian Nordic A/S, ViRAZE, HK inno.N, and others.

 

  • Smallpox pipeline therapies- FD MVA-BN, Vaccinia virus: ACAM2000 smallpox vaccine, MVA-BN® (IMVAMUNE), TPOXX, and others.

 

  • Smallpox Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Smallpox Pipeline Companies and Therapies, click here @ Smallpox Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Smallpox: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Smallpox – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Smallpox Collaboration Deals
  9. Late Stage Products (Prergistration)
  10. Brincidofovir: Chimerix
  11. Drug profiles in the detailed report…..
  12. Preclinical and Discovery Stage Products
  13. IN-B002: HK inno.N
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Smallpox Key Companies
  17. Smallpox Key Products
  18. Smallpox- Unmet Needs
  19. Smallpox- Market Drivers and Barriers
  20. Smallpox- Future Perspectives and Conclusion
  21. Smallpox Analyst Views
  22. Smallpox Key Companies
  23. Appendix

 

Got Queries? Find out the related information on Smallpox Mergers and acquisitions, Smallpox Licensing Activities @ Smallpox Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles